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ABSTRACT
Use of SPR-based biosensors is an established
method for measuring molecular interactions. Their
application to the study of GPCRs is nonetheless lim-
ited to detergent-solubilized receptors that can then
be reconstituted into a lipid environment. Using the
chemokine receptor CXCR4 and its specific ligand
CXCL12, we outline here a highly reproducible biosen-
sor method based on receptor presentation on the
surface of lentiviral particles; the approach is simple
and does not require the use of antibodies to achieve
correct receptor orientation on the sensorchip sur-
face. We measured the kinetic parameters of CXCR4/
CXCL12 binding in a single step and in real time and
evaluated the effect of GAG presentation of chemo-
kines on this interaction. The data indicate that at low
concentrations, soluble heparin modulates CXCR4/
CXCL12 interaction and at high concentrations, abro-
gates binding. These observations suggest that in ad-
dition to their known role in modulating local chemo-
kine availability, GAG affect the receptor/ligand
interaction, although their influence on affinity param-
eters is very limited. The method will also be useful
for quantifying these biomarkers in biological fluids
and for the development of high-throughput screen-
ing for their antagonists. J. Leukoc. Biol. 90:
000–000; 2011.
Introduction
A number of genes encode the GPCR, a family of proteins
characterized by seven -helical domains that span the cell
membrane; these proteins include receptors for hormones,
neurotransmitters, chemokines, and calcium ions, among oth-
ers. The transmembrane-spanning -helices make the receptor
extremely hydrophobic, and it requires a lipid environment to
maintain its native conformation [1]. The GPCR are thus sen-
sitive to solubilization; detergents can render these proteins
nonfunctional, as solubilized receptors undergo conforma-
tional changes that alter or impede their ability to bind the
ligand [2]. For this reason, ligand-binding analysis and ago-
nist/antagonist screening are done mainly using intact cells.
SPR-based biosensors are established tools for measuring
molecular interactions and could thus provide an ideal
method to evaluate GPCR-binding interactions [3]. Biosen-
sor experiments involve immobilizing a biomolecule on a
sensor surface and monitoring its interaction with a second
molecule in solution. SPR biosensors detect association/
dissociation of a biomolecular interaction by measuring
changes in the refractive index over the binding surface;
binding reactions can thus be evaluated in real time with no
labeling requirement [4]. Some attempts have been re-
ported using biosensors to study membrane-associated
GPCR; in all these cases, the method is based on capture of
detergent-solubilized GPCR prior to their reconstitution in
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a lipid environment [5]. These methods require use of de-
tergents and substantial purification prior to analysis. An-
other important question is receptor capture on the biosen-
sor surface, as uniform receptor orientation on the chip is
difficult to achieve in these conditions. Some techniques
use a two-step protocol, based on capture of the solubilized
receptor with mAb, and reconstitution of a lipid bilayer en-
vironment [6]. Although these methods resolve the receptor
orientation problem, the element of variability remains a
result of detergent solubilization of the receptor [6].
Chemokines are potent chemoattractant cytokines that regu-
late leukocyte trafficking in homeostatic and inflammatory
processes [7]. Depending on their local concentration, which
is facilitated by their association to GAG [8], chemokines can
recruit circulating leukocytes to a site of inflammation or in-
jury. They act by binding to GPCR; one of these, CXCR4, is
also expressed on the surface of various cancer cell types [9].
Mice with gene deletions for CXCR4 or its chemokine ligand,
CXCL12, have an identical lethal phenotype, indicating a
highly specific receptor/ligand relationship. Mice lacking
CXCR4 die perinatally and show defective vascular develop-
ment, hematopoiesis, and cardiogenesis [10]; CXCL12-defi-
cient mice are characterized by defective B cell lymphopoiesis
and myelopoiesis, as well as abnormal neuronal and cardiovas-
cular development [11]. The CXCR4/CXCL12 axis is also im-
plicated in rheumatoid arthritis [12] and pulmonary fibrosis
[13]. Finally, together with CCR5, CXCR4 is one the main co-
receptors for HIV-1 infection [14].
Using CXCR4 and CXCL12 as a model, we outline a biosen-
sor-based method to determine their binding parameters. Our
technique circumvents the limitations of the direct immobiliza-
tion approach as well as use of detergents. During budding
from the cell surface, viruses pull away membrane fragments
bearing proteins in their lipid environment; our method takes
advantage of this property to present CXCR4 on the surface of
lentiviral particles. We found that CXCR4 and probably other
receptor types in the context of the cell membrane are incor-
porated into virions that can be purified easily and attached to
the biosensor surface. Binding of specific antibodies and of
CXCL12 demonstrated structural integrity of CXCR4 and spec-
ificity of the interaction. Other chemokines did not interact,
and CXCL12 binding was abrogated by incubation of the lenti-
viral particles with the CXCR4 antagonist AMD3100 [15]. The
use of lentiviral particles allowed us to determine real-time
binding parameters for the CXCR4/CXCL12 interaction and
to compare the effect on binding of GAG association with
chemokines. This approach enables straightforward evaluation
of the binding of intact chemokines, their quantification in
biological fluids, and high-throughput screening for their an-
tagonists.
MATERIALS AND METHODS
Cells and reagents
HEK293T (CRL-11268), HT29 human colon carcinoma cells (HTB-38),
and HeLa human cervical adenoma cells (CCL2) were from the American
Type Culture Collection (Manassas, VA, USA; CRL-11268). Antibodies were
anti-CXCR4-01 [16], -CXCR4 (12G5), and -CXCR4-biotin (12G5, R&D Sys-
tems, Minneapolis, MN, USA); anti-p24 and -VSVG mAb (Abcam, Cam-
bridge, UK); anti-Syndecan-4 mAb (Santa Cruz Biotechnology, Santa Cruz,
CA, USA); anti-human CD44-PE (BD Biosciences, San Diego, CA, USA);
and anti-CD9 (VJ1/20) mAb (kindly donated by Dr. Francisco Sa´nchez-
Madrid, Hospital de la Princesa, Madrid, Spain). When needed, we used
avidin-PeCy7 (BD Biosciences) and anti-mouse IgG (HL) (Southern Bio-
technology, Birmingham, AL, USA). Heparan sulfate (H7640), heparin
(B9806), chondroitin sulfate (C9819), and AMD3100 were from Sigma-Al-
drich (St. Louis, MO, USA); CXCL12, CCL2, and CCL3 were from Pepro-
Tech (Rocky Hill, NJ, USA).
siRNA constructs and transfection
We designed two different siRNA duplexes of CXCR4: siRNA1 (sense, 5-
UAAAAUCUUCCUGCCCACCdTdT-3) and siRNA2 (sense, 5-GGAAGCU-
GUUGGCUGAAAAdTdT-3; Dharmacon, Lafayette, CO, USA). Nonspecific
control siRNA duplexes had the same GC content as CXCR4 siRNA (42%,
D001206-10, Dharmacon). HEK293T cells were cultured in RPMI 1640,
supplemented with 10% FBS (both from Sigma-Aldrich) at 37°C in 5%
CO2. siRNA were transfected into HEK293T cells at a final concentration
of 120 nmol/L using JetPei (Polyplus, Illkirch, France).
Virion production, purification, and characterization
Lentiviral particles (X4LP) were produced by JetPei cotransfection of
HEK293T cells with the LVTHM, PAX2, and VSVG plasmids (Tronolab,
Lausanne, Switzerland) at a 1:1:1 ratio. When necessary, CXCR4 siRNA or
CXCR4 was cotransfected with the viral plasmids. At 72 h post-transfection,
the supernatant was harvested and cell debris removed by low-speed cen-
trifugation and 0.45 m filtration, pelleted in a Beckman SW55 rotor
(247,000 g, 2 h, 4°C) through a 20% sucrose cushion, and the pellet resus-
pended in PBS. A second centrifugation step, through a 20–50% sucrose
gradient, was performed in a Beckman SW41 rotor (281,000 xg, 45 min,
4°C). The fraction with particles was centrifuged (247,000 xg, 1 h, 4°C) to
eliminate sucrose. Finally, lentiviral particles were aliquoted and stored at
–80°C.
Lentiviral particles were analyzed for VSVG protein, the structural pro-
tein p24, and CXCR4 expression by SDS-PAGE and Western blot [16] us-
ing specific antibodies and silver staining [17].
Different batches of lentiviral particles were standardized by titration
using HEK293T cell transduction. Cells were transduced with twofold serial
dilutions of viral particles; after 72 h, GFP expression was analyzed by
FACS. Lentiviral particles with a similar titration index were aliquoted and
stored at –80°C.
Flow cytometry analysis
HEK293T, HeLa, or HT29 cells were plated in V-bottom 96-well plates
(2.5105 cells/well) and incubated (30 min, 4°C) with 10 l/well biotin-
labeled anti-CXCR4 mAb (0.05 g/l), followed by avidin-PECy7 or with
50 l/well PE-labeled anti-human CD44 mAb (0.01 g/l). Cell-bound
fluorescence was determined in a Profile XL flow cytometer (755 nm,
Coulter, Miami, FL, USA).
To evaluate lentiviral particles by flow cytometry, virions were cou-
pled to latex beads. After sonication (5 min, RT), beads (4 m, 4%
w/v; A37304, Invitrogen, Eugene, OR, USA) were mixed with lentiviral
particles (107/ml) at a 1:1 v/v ratio (15 min, RT). PBS was added, and
the final suspension was incubated (60 min, 4°C, with continuous rock-
ing). The reaction was terminated by adding 100 mM glycine (30 min,
RT). Beads coupled to lentiviral particles were washed twice by centrifu-
gation (3 min, 2000 xg) using washing buffer (PBS/BSA 0.5%). The pel-
let was resuspended in washing buffer and stained as above for flow cy-
tometry analysis.
Immunofluorescence analysis
HEK293T, HT29, or HeLa cells (5104 cells/well) were plated on poly-l-
lysine-coated coverslips (20 g/ml, 1 h, 37°C; Sigma-Aldrich) and cultured
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(24 h, 37°C). Cells were washed in cold PBS and fixed with 4% paraformal-
dehyde (3 min, RT). To avoid nonspecific binding, cells were treated with
PBS, supplemented with 1% BSA, 0.1% goat serum, 10% mouse serum,
and 150 mM NaCl (1 h, 37°C), and then stained with antisyndecan mAb
(0.5 g/106 cells, 30 min, RT), followed by Alexa 488-goat anti-mouse IgG
(Invitrogen). As a control, cells were stained with anti-CD9 mAb [18], fol-
lowed by Cy3-goat anti-mouse IgG (Jackson ImmunoResearch, West Grove,
PA, USA). Fluorescence was evaluated on a Zeiss Axiovert LSM 510-META
inverted microscope with a 63 oil immersion objective (aperture 1:40)
and processed using ImageJ 1.43 software.
ELISAs
Lentiviral particles (107 in 100 l PBS) were adsorbed to microtiter plates
(Maxisorb, Nunc, Denmark; 90 min, 37°C). Remaining protein-binding
sites were blocked with 0.5% BSA in PBS. Plates were washed, incubated
with anti-CXCR4 or isotype control mAb (1 h, 37°C), followed by peroxi-
dase-labeled goat anti-mouse IgG (Tago, Burlingame, CA, USA) and o-phe-
nylene diamine (Sigma-Aldrich). The reaction was terminated with 3 N sul-
furic acid and OD determined at 492 nm.
Immunogold detection of virions
Lentiviral particles were examined by negative-stain EM on carbon
grids. Samples were incubated with 30 g/ml CXCR4-01 antibody in
PBS/0.5% BSA (15 min, RT), followed by a 10-nm gold-conjugated anti-
IgG  IgM antibody (British Biocell, Cardiff, UK; 15 min, RT). After
washing, samples were treated with 2% uranyl acetate (30 s, RT). EM
grids were examined in a transmission electron microscope (1200-EX II;
Jeol, Tokyo, Japan) at 100 kV.
Quantitation of receptor number
HEK293T cells were transiently cotransfected with plasmids, as indicated
above, and incubated in DMEM supplemented with 10% FCS (24 h, 37°C,
5% CO2); cells were then washed twice with Met-free DMEM and main-
tained in this medium supplemented with 35S-Met (50 Ci/ml, 48 h, 37°C,
5% CO2).
35S-Met-labeled viral particles were collected and purified as
above. Samples of the purified particles were used to prepare a doubling
dilution series. Identical volumes of these dilutions were loaded onto 12%
polyacrylamide gels, resolved by SDS-PAGE, dried on 3-MM filter paper
(Whatman, UK), and visualized by phosphorimaging (Storm 869, Molecu-
lar Dynamics, Sunnyvale, CA, USA). Relative CXCR4 stoichiometry within
the viral particle was calculated using Quantity One software (BioRad, Her-
cules, CA, USA) [19]. Intensity of bands corresponding to the structural
p24 viral protein and CXCR4-01 antibody was determined and normalized
considering the number of Met residues (11 and 6 for p24 and CXCR4,
respectively). The relative number of CXCR4 molecules was calculated by
interpolating the intensity values of the sample dilutions onto the regres-
sion curve for the p24 data used as an internal standard. The results of
three independent experiments indicate that the number of CXCR4 mole-
cules incorporated into the viral envelope corresponded to 10% of the
number of p24 monomers in the virus core structure; assuming 2100 p24
molecules/virus particle [20], the envelope of our purified lentivirus prepa-
rations thus contained an average of 210  19 CXCR4 molecules. A similar
analysis indicated that lentiviral particles, obtained from CXCR4 transiently
transfected HEK293T cells (X4X4LP), had an average of 530  45
CXCR4/virion.
Immobilization of lentiviral particles on the
sensorchip
To activate the carboxymethylated dextran, equal volumes of 0.1 M NHS
and 0.4 M EDC were mixed and injected (5 l/min, 7 min, RT) over the
surface of a CM5 sensorchip (GE Healthcare, Pittsburgh, PA, USA). Hepes-
buffered saline-P [10 mM Hepes, 0.15 M NaCl, 0.005% polyoxyethylenesor-
bitan (P20), pH 7.4] was used as immobilization running buffer. Lentiviral
particles (107/ml) diluted in sodium acetate buffer (10 mM, pH 4.0) were
injected over the activated surfaces (5 l/min, 7 min, RT), followed by eth-
anolamine (1 M, pH 8.5, 5 l/min, 7 min, RT) to deactivate remaining
active carboxyl groups. We usually detected 6000 RU coupled lentiviral par-
ticles. All determinations were performed using a Biacore 3000 (GE
Healthcare).
Kinetic assays on the Biacore
CXCL12 (25–400 nM), diluted in PBS-P buffer (137 mM NaCl, 10 mM
Na2HPO4, 1.76 mM KH2PO4, 2.7 mM KCl, 0.005% P20, pH 7.4), was
injected over the immobilized viral particles (30 l/min, 3 min, 25°C;
association phase), followed by a 2-min injection period of PBS-P buffer
alone over the surface (dissociation phase). Sensorgrams were corrected
for signals obtained in the reference flow channel, a control chamber
without viral particles, which was activated and deactivated in parallel.
All kinetic assays were followed by injection of 5 mM HCl to dissociate
remaining ligand from the virions (regeneration phase). All steps were
performed using the system’s automated robotics; all phases were fol-
lowed in real time as a change in signal expressed in RU. Curves de-
rived from these assays were used to generate kinetic constants, which
were analyzed by fitting to a simple one-site interaction model with Bi-
aevaluation 4.1 software (Biacore). Alternatively, dissociation constants
were derived from the response at equilibrium to corroborate findings
from the automated kinetic analyses, although for simplicity, only these
last data are included in the manuscript.
When required, CXCL12 was preincubated with different GAG at indi-
cated concentrations (30 min, 37°C) before injection over viral particles as
for ligand alone. Signals were corrected as for chemokine alone and for
signal produced by injection of uncomplexed GAG over the immobilized
virions (control).
Statistical analysis
Levels of statistical significance among kon, koff, and KD were calculated by
Student’s t test (Prism 5.0 software; Prism, Irvine, CA, USA).
Online Supplemental Material
Supplemental Fig. 1 shows, by immunofluorescence analysis with specific
antibodies, that HEK293T cells do not express syndecan-4 proteoglycans at
the cell surface. Supplemental Fig. 2 shows by flow cytometry analysis with
specific mAb that HEK293T cells do not express CD44 proteoglycans at the
cell surface. Supplemental Fig. 3 shows the overlay of the mathematical fit-
tings with the experimental traces corresponding to the kinetic analysis of
CXCL12/CXCR4 interactions using X4LP, as well as the overall 2 value
for this fitting.
RESULTS AND DISCUSSION
Lentiviral particles express CXCR4 at the particle
surface
Flow cytometry analysis using anti-CXCR4 mAb confirmed
endogenous CXCR4 expression by HEK293T cells (Fig. 1A).
These cells were transiently cotransfected with plasmid
LVTHM, PAX2, and VSVG plasmid and supernatant col-
lected at 72 h. After purifying the viral particles (X4LP) on
a sucrose gradient, we evaluated CXCR4 in Western blot
using the CXCR4-01 mAb (Fig. 1B). Control anti-p24 and
-VSVG mAb detected specific bands only in X4LP lysates.
The presence of CXCR4 in X4LP was confirmed by ELISA
using specific anti-CXCR4 mAb on lentiviral particle-coated
plates (Fig. 1C) and by EM techniques with specific antibod-
ies (Fig. 1D).
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To determine CXCR4 levels in the virions, we transiently
transfected HEK293T cells, as above in 35S-Met-supplemented
medium. After 72 h, X4LP particles were collected and puri-
fied on sucrose gradients, lysed, and resolved in SDS-PAGE.
Bands corresponding to the structural p24 viral protein and
CXCR4 were identified by Western blot. The relative amount
of 35S-Met-labeled CXCR4 was quantified using p24 as stan-
dard reference [19]. Based on these results, purified X4LP
were estimated to contain an average of 210 CXCR4 mole-
cules/virion (Fig. 1E).
GAG are expressed at the membrane of many cell types
[21]. As these polysaccharides also bind chemokines, their
presence can interfere with measurement of the binding pa-
rameters for the CXCL12/CXCR4 pair. During cell budding,
lentiviruses pull away HEK293T cell membrane fragments that
contain not only CXCR4 but also other cell components, such
as heparan sulfate proteoglycans. As syndecan-4 and CD44
bind chemokines [22, 23], HEK293T cells were stained with
antisyndecan-4 mAb and analyzed by immunofluorescence
(Supplemental Fig. 1) or with anti-CD44 and analyzed by
FACS (Supplemental Fig. 2). As positive controls, staining of
HT29 fibroblasts and HeLa cells was also analyzed. In accor-
dance with previous reports [24, 25] of the possible heparan
sulfate proteoglycans, neither synthecan-4 nor CD44 GAG was
detected on the surface of HEK293T cells used to prepare len-
tiviral particles. As control, all cells showed surface expression
of CD9 (Supplemental Fig. 1).
X4LP particles bind specifically to CXCL12
Previous studies using a retroviral, particle-based strategy
showed that biosensors can be used successfully to analyze
binding of anti-CXCR4 mAb and to demonstrate association
between CXCR4 and the HIV-1 envelope protein gp120 [26].
Moreover, incorporation of CD4 and CCR5 or CXCR4 into
viral particles enables them to infect cells expressing gp120
from HIV-1 R5 or X4 viruses [27, 28], indicating that receptor
conformation in the virions resembles that on cell membranes.
We immobilized X4LP on a CM5 sensorchip (Fig. 2A) and
determined anti-CXCR4 mAb binding at a concentration of 30
g/ml. CXCR4-01 bound X4LP, shown by a steady increase in
the SPR signal following the initial bulk-refractive index
change during the association phase and by steady dissociation
after termination of analyte injection (Fig. 2B). Interaction
specificity was corroborated by isotype control mAb, which
showed almost no binding (Fig. 2B). Results were similar using
the anti-CXCR4 mAb 12G5 (20 g/ml, 30 l/min, 3 min, RT;
Fig. 2C). As this antibody recognizes correct CXCR4 folding,
the data indicate correct CXCR4 conformation on the virions.
The antibody injection gave a fairly low signal (maximum
120 RU at the end of injection and 48 at the beginning of
spontaneous dissociation, 30 s after PBS-P buffer injection).
Based on the level of particle immobilization (6000 RU), on
the estimated MW of the particles (1.5108 g/mol), and on
receptor copy number/particle, the maximum theoretical re-
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Figure 1. CXCR4 is expressed at the surface of X4LP particles. (A) Membrane expression of
CXCR4 in HEK293T cells was analyzed by flow cytometry using specific mAb. One representative
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in Western blot with anti-p24, -VSVG, and -CXCR4 mAb. (C) CXCR4 recognition by anti-CXCR4
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body (arrows). Original scale bar  50 nm. (E) Estimation of the number of CXCR4 molecules in
purified X4LP particles. SDS-PAGE and autoradiography of a twofold dilution series from a repre-
sentative sample of 35S-Met-labeled, purified X4LP. The position of the VSVG, CXCR4, and p24
polypeptides is indicated.
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sponse would be 600 RU. As the particles are immobilized in
a 3D matrix, it is plausible that a fraction of the particle sur-
face is inaccessible to the antibodies. The fact that the IgM is a
large molecule entails a negative-steric effect on the binding of
other Ig molecules to neighboring binding sites. To confirm
the correct CXCR4 conformation on the viral particles, we
evaluated ligand binding. A 200-nM CXCL12 solution was in-
jected onto the X4LP-coated sensorchip; CXCL12 bound
X4LP, whereas no interaction was observed in the reference
flow cell (Fig. 2D). No binding was detected after control in-
jections of the CCR2-specific ligand CCL2 or the CCR5 ligand
CCL3 (both 200 nM; Fig. 2D).
As a specificity control for CXCL12/CXCR4 interactions,
lentiviral particles from CXCR4 siRNA transiently transfected
HEK293T cells were prepared (siX4LP). Compared with
X4LP, siX4LP showed residual levels of CXCR4, as indicated
by FACS analysis using anti-CXCR4 mAb (Fig. 2E). CXCL12
solution (200 nM) showed no interaction on siX4LP immobi-
lized (6000 RU) on a CM5 sensorchip (Fig. 2F). The sensor-
grams were in fact similar to that obtained when the control
chamber without viral particles, activated and deactivated in
parallel, was used. These results not only confirm signal speci-
ficity but also facilitated later analysis, as they allowed the use
of the control chamber without viral particles as a reference
flow channel.
To verify the chip-regeneration process and determine
measurement reproducibility, we repeated 20 cycles of
CXCL12 injection and chip regeneration, which showed
10% variation in the CXCL12 response. As an additional
specificity control, we tested the ability of AMD3100, a small
molecule that blocks CXCL12 binding to CXCR4 [15], to
modify the CXCL12 signal. AMD3100 (50 M) was injected
(5 l/min, 20 min, RT), followed by a CXCL12 (100 nM)
solution containing 50 M AMD3100 (30 l/min, 3 min,
RT). There was a clear reduction in CXCL12 binding to
X4LP in the presence of AMD3100 (Fig. 2G). Given the low
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(G) Effect of AMD3100 pretreatment of the X4LP surface on CXCL12 binding. Maximum RU were obtained for 100 nM CXCL12 binding to un-
treated or AMD3100-treated X4LP sensorchips; signals for CXCL12 binding to the untreated or treated reference sensorchip have been sub-
tracted. Values as a percentage of maximum binding are the mean  sd of five independent experiments.
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MW of the inhibitor (794.5 daltons) and the fairly low
CXCR4 density on the sensorchip, this technique did not
permit direct visualization of AMD3100/CXCR4 interac-
tions. Our results indicate that X4LP particles immobilized
on the sensorchip bear CXCR4 that binds specifically to its
ligand, CXCL12. Other studies used antibodies to retain vi-
rus particles on the sensorchip surface [5]; here, particles
were covalently attached to activated, carboxymethylated
dextran on the sensorchip surface through standard amine-
coupling chemistry. Compared with the noncovalent anti-
body-receptor interaction, the covalent interaction in our
immobilization protocol allows multiple regenerations and
thus, a larger number of experiments using a single surface.
Our 3D particle environment was extremely stable; sensor-
chip surfaces were regenerated more than 100 times with
no appreciable change in particle ability to bind CXCL12
(maximum signal loss 30 RU).
Binding parameters of CXCL12 to CXCR4 on X4LP
virions
Real-time SPR biosensor measurements enable direct analysis
of interactions between chemokines and their receptors, by-
passing the manipulation involved in protein labeling. After
confirming specific, reproducible CXCL12 binding to CXCR4-
expressing X4LP, we analyzed the kinetic parameters of this
interaction. Experiments were performed using various
batches of viral particles produced over a 2-year period, as well
as different sensorchips with multiple repetitions (at least trip-
licates) on each chip and in two independent laboratories on
distinct Biacore instruments, which yielded similar, reproduc-
ible results. CXCL12 solutions (25–400 nM) in PBS were in-
jected individually onto sensorchips (30 l/min, 3 min, RT).
After each injection, chips were regenerated with 5 mM HCl.
As a reference, solutions were injected in parallel over a flow
cell lacking X4LP particles. After subtracting reference flow
cell values, we observed maximum response signals in the asso-
ciation phase of 100 RU and minimum values of 15 RU
(Fig. 3A). Sensorgrams were processed using Biaevaluation 4.1
software, adjusting experimental curves to 1:1 Langmuir-bind-
ing models, as no other stoichiometry of CXCL12/CXCR4
binding was predicted, and the demonstrated lack of CXCL12
binding to X4LP particles in the presence of AMD3100 ruled
out possible competitive-binding phenomena. The resulting
plot of response at equilibrium versus ligand concentration
showed a maximum response signal of 20 RU (CXCL12, 400
nM) and a minimum value of 7 RU (CXCL12, 25 nM; Fig.
3B). Binding parameter experiments gave similar results when
repeated at least four times using different X4LP particles and
were, as such, averaged. Binding parameters were kon 4.20 
0.56  105 M s–1; koff 8.24  0.11  10
	3 s–1; and KD 3.47 
0.05  10	8 M (Fig. 3B and Supplemental Fig. 3). Alterna-
tively, a dissociation constant was also established from the re-
sponse units at equilibrium, corroborating the findings from
the mathematical fittings (not shown).
These results correlate with previous data obtained with
Scatchard analysis [29–31] and demonstrate the use of this
method for evaluating chemokine binding. Our data show
higher affinity for chemokine binding than the value ob-
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tained in the two-step biosensor method (156–180 nM) [6].
This divergence might be a result of the use, in those ex-
periments, of detergent-solubilized CXCR4 immobilized on
L1 chips before lipid reconstitution, differences in lipid
composition from that of the cell membrane included in
the lentiviral particles, lack of specific membrane proteins
that modulate ligand binding, or even differences in the
conformation adopted by the receptors.
To determine whether intrinsic CXCR4 expression levels
influence the kinetic parameters of CXCL12/CXCR4 inter-
actions, CXCR4 transiently transfected HEK293T cells were
used to prepare new viral particles (X4X4LP). As predicted,
these new particles showed higher CXCR4 levels at the sur-
face, shown by FACS analysis using the CXCR4-01 mAb and
viral particle-coated beads (Fig. 2E). For X4X4LP, the num-
ber of receptor molecules/virion was determined as 530
CXCR4. SPR experiments, using these particles on a CM5
sensorchip at comparable immobilization levels and with
CXCL12 solutions (25–400 nM, 30 l/min, 3 min, RT),
yielded a maximum response in the association phase of
150 RU (30 RU in the response at equilibrium vs. ligand
concentration plot) and a minimum of 20 RU (10 RU in
the response at equilibrium vs. ligand concentration plot;
Fig. 3C and D). Binding parameters were again determined
from a minimum of four replicates using different batches
of X4X4LP particles; values were kon 3.43  0.34  10
5 M
s–1; koff 13  0.5  10
	3 s–1; and KD 3.69  0.18  10
	8 M
(Fig. 3D). Results indicated that CXCR4 levels on virions
affected the maximum signal, although not in a linear man-
ner, as a result of the intrinsic 3D properties of the viral
particles (see above), but did not affect kinetic binding pa-
rameters. The receptor levels are thus important for estab-
lishing the biosensor detection limit and should be consid-
ered when the technique will be used in antagonist screen-
ings or to detect these proteins in biological fluids. Our
results also indicate that at least in the case of CXCR4, the
use of untransfected cells, which facilitates viral particle
production, provides a signal sufficient for calculation of
binding parameters and that endogenous CXCR4 levels at
the cell surface are sufficient to permit CXCL12 detection.
Effect of GAG on CXCL12 binding to CXCR4
The use of a real-time biomolecular interaction analyzer
permits precise measurement of kon and koff values. These
data are of maximum importance for evaluating the effect
of other molecules on chemokine receptor/ligand associa-
tion/dissociation rates. GAG are normally expressed
strongly at the cell surface and constitute an extensive net-
work of chemokine binding sites. This binding is function-
ally important, as it enhances the local chemokine concen-
tration in the vicinity of the receptor and allows formation
of chemotactic gradients [32–34]. GAG/chemokine com-
plexes therefore facilitate chemokine/receptor binding [35,
36]. CXCL12 shows affinity for heparin and heparan sulfate
[37, 38] through interactions based on specific residues on
CXCL12 [39].
As the HEK293T cells used here to prepare the lentiviral
particles expressed neither syndecan-4 nor CD44 heparan
sulfate proteoglycans at the cell surface (Supplemental Figs.
1 and 2), AMD3100 pretreatment of lentiviral particles abro-
gated the CXCL12 signal, and other chemokines did not
associate to virions, binding in our experimental conditions
was a result of CXCR4 and not of other lentiviral particle
components. This system could thus be used to test the ef-
fect of GAG on CXCR4/CXCL12 binding. We incubated
CXCL12 (200 nM, 30 min, 37°C) with increasing concentra-
tions of heparin or heparan sulfate (7.8 ng/ml–4 g/ml),
and solutions were injected (30 l/min, 3 min, RT) into
sensor flow cells alone or with virions. The signal triggered
by injection of heparin or heparan sulfate alone into X4LP-
containing chambers was subtracted to establish the specific
signal of GAG/CXCL12 complexes on CXCR4. Low heparin
concentrations complexed with CXCL12 did not modify the
signal for CXCL12 alone (90 RU for 7.8 ng/ml), but hep-
arin concentrations 1 g/ml reduced CXCL12 binding to
CXCR4 (Fig. 4A); results were similar for heparan sulfate
complexes (not shown). These data concur with reports
that high concentrations of soluble GAG compete with
chemokine/chemokine receptor binding [40]. These obser-
vations contrast with reports showing clear structural separa-
tion between the CXCL12 domains involved in receptor (N-
loop) and GAG binding (1 and 2 strands) [38, 41]. Nu-
clear magnetic resonance spectroscopy and X-ray
crystallography analyses showed two CXCL12 structural do-
mains for heparin or heparan sulfate binding: one corre-
sponding to the -strands at the dimer interface and the
second in the motif involved in receptor binding, that is,
the N-terminal and -helix region [42]; these findings clar-
ify the inhibitory effect of high GAG concentrations on
CXCR4/CXCL12 binding. High GAG concentrations block
the CXCL12 N-terminal domain, inhibiting CXCR4/
CXCL12 binding. The N-terminal domain is unaffected at
low GAG concentrations, allowing CXCL12:receptor bind-
ing. Our results are also consistent with results using 125I-
CXCL8 and 125I-CCL3 with CXCR1-, CXCR2-, or CCR1-
transfected CHO cell membranes [36], as well as with data
from various laboratories showing that soluble heparin and
heparan sulfate inhibit leukocyte responses [40, 42]. Un-
fractionated heparin and the low MW heparin Tinzaparin
inhibit CXCL12 binding to CXCR4-expressing CHO cells
and human breast cancer cell lines, thus blocking signaling;
these compounds might be useful in preventing chemokine-
driven breast cancer metastasis [43].
Our findings show that only certain GAG (heparin and
heparan sulfate but not chondroitin sulfate) affect CXCR4/
CXCL12 binding. We have nonetheless observed that inde-
pendently of the GAG concentration used, there was a weak
effect on binding when CXCL12 was coinjected with the
nonspecific GAG chondroitin sulfate A (Fig. 4B). At high
heparin or heparan sulfate concentrations, the GAG/
CXCL12 complex interfered with chemokine binding to its
receptor by blocking of the CXCL12 N-terminal region, as
shown by structural studies [38]. Moreover, the reduced im-
pact of GAG on the SPR readout yielded nearly overlapping
sensorgrams in the association and dissociation phases (Fig.
4). At a threshold GAG concentration (500 ng/ml in our
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SPR conditions), GAG interference is not evident in the dis-
sociation phase but is detected as a lower association curve;
this phenomenon is unambiguous in association and dissoci-
ation curves at GAG concentrations 1 g/ml. GAG inter-
ference is best visualized in the SPR experiments when the
contribution of individual sample components (GAG,
CXCL12) is subtracted from sensorgrams (Fig. 4A, right),
allowing definition of the threshold concentration (at which
the dissociation phase shows a null response, indicating lack
of residual binding after termination of analyte injection).
Based on these data, we used a heparin:chemokine complex
(7.8 ng/ml heparin and 200 nM CXCL12) to evaluate bind-
ing, which allowed maximum binding to the receptor with
no interference compared with chemokine alone.
Solutions of increasing heparin/CXCL12 concentrations
at a constant ratio (7.8 ng/ml/200 nM) were injected into
X4LP and control flow cells (30 l/min, 3 min, RT). Sens-
orchip surfaces were regenerated with 5 mM HCl. Maxi-
mum- and minimum-specific responses were 100 RU and
20 RU for the association phases (Fig. 4C). Sensorgrams
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Figure 4. Effect of GAG on
CXCL12 binding to CXCR4.
(A) Sensorgrams of 200 nM
CXCL12 binding, alone or incu-
bated with increasing concentra-
tions of heparin (7.8 ng/ml–4 g/
ml), to the X4LP-coated surface.
Individual signals were subtracted
for CXCL12 and for heparin bind-
ing to the reference sensorchip
and for heparin binding to the
X4LP-coated surface. Association
was measured for 180 s and disso-
ciation for 325 s before regenera-
tion (left). From these values, we
subtracted the signal for CXCL12
(200 nM) binding to the X4LP-
coated surface (right). One repre-
sentative experiment is shown of at
least four performed. (B) Sensor-
grams of 200 nM CXCL12 bind-
ing, alone or incubated with in-
creasing concentrations of chon-
droitin sulfate A (125 ng/ml–4
g/ml), to the X4LP-coated sur-
face. Individual signals were sub-
tracted for CXCL12 and for chon-
droitin sulfate A binding to the
reference sensorchip and for chon-
droitin sulfate A binding to the
X4LP-coated surface. Association
and dissociation were measured as
in A before regeneration (left);
from these values, the CXCL12
signal was subtracted as in A
(right). One representative experi-
ment is shown of at least four per-
formed. (C) Sensorgrams for hepa-
rin/CXCL12 complex binding at a
1:384 ratio to X4LP virions immo-
bilized on the sensorchip surface.
Aliquots of heparin/CXCL12 com-
plexes at indicated concentrations
were injected sequentially into the
flow cell and binding monitored in
RU on the sensorgram. Association
was measured for 180 s and disso-
ciation for 185 s before regenera-
tion. Heparin/CXCL12 binding
signal to the reference sensorchip
was subtracted. One representative
experiment is shown of at least
four performed.
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processed as above showed that binding parameters differed
from those for CXCL12 alone (kon 5.490.1410
5 M s–1;
koff 1.630.1010
	3 s–1; KD 6.670.0110
	8 M; Fig. 4C).
These data indicate that heparin not only modulated
CXCL12 availability in the medium but also significantly re-
duced CXCL12 affinity for CXCR4 binding (3.470.0510	8 M
for CXCL12 alone; 6.670.0110	8 M for the heparin/
CXCL12 complex; P0.01). Differences are attributed to a
higher dissociation rate for heparin/CXCL12 complexes
(8.240.1110
	3
s–1 for CXCL12 alone; 1.630.1010	3 s-1
for complexes; P0.001). Although statistically significant,
the narrow margin between the KD and koff values for the
chemokine alone or in complex with heparin nonetheless
suggests limited influence of these parameters on the biol-
ogy of these inflammatory mediators.
The use of lentiviral particles to present cell membrane
proteins allows detailed study of ligand interactions using
optical biosensors in conditions that resemble the in vivo
situation, lipid composition of the cell membrane, receptor
conformations, and presence of other proteins that modu-
late binding parameters. The approach has clear use for
drug discovery research, as it facilitates screening for ago-
nist/antagonist effects and simplifies biomarker detection in
biological fluids.
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